Development of an ErbB4 monoclonal antibody that blocks neuregulin-1-induced ErbB4 activation in cancer cells

Biochemical and Biophysical Research Communications
Shogo OkazakiOsamu Nagano

Abstract

The use of monoclonal antibodies (mAbs) for cancer therapy is one of the most important strategies for current cancer treatment. The epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, which regulates cancer cell proliferation, survival, and migration, is a major molecular target for antibody-based therapy. ErbB4/HER4, which contains a ligand-binding extracellular region, is activated by several ligands, including neuregulins (NRGs), heparin-binding EGF-like growth factor, betacellulin and epiregulin. Although there are clinically approved antibodies for ErbB1 and ErbB2, there are no available therapeutic mAbs for ErbB4, and it is not known whether ErbB4 is a useful target for antibody-based cancer therapy. In this study, we developed an anti-ErbB4 mAb (clone P6-1) that suppresses NRG-dependent activation of ErbB4 and examined its effect on breast cancer cell proliferation in the extracellular matrix.

References

Dec 2, 1993·Nature·G D PlowmanS Buckley
Sep 2, 1997·Proceedings of the National Academy of Sciences of the United States of America·D ZhangP J Godowski
Jun 12, 2001·Current Opinion in Neurobiology·A Buonanno, G D Fischbach
Mar 22, 2003·Experimental Cell Research·Graham Carpenter
Jun 26, 2003·Proceedings of the National Academy of Sciences of the United States of America·Hester TidcombeJon P Golding
Jul 16, 2004·Journal of Cellular Physiology·Patrizia CasaliniSylvie Ménard
Mar 1, 2005·Cancer Research·Teemu T JunttilaKlaus Elenius
Aug 18, 2006·Molecular and Cellular Biology·Rebecca S Muraoka-CookH Shelton Earp
Mar 31, 2007·Nature Methods·Genee Y LeeMina J Bissell
Mar 23, 2012·Nature Reviews. Cancer·Andrew M ScottLloyd J Old

❮ Previous
Next ❯

Citations

Mar 10, 2018·PLoS Genetics·Ulrika A HänninenLauri A Aaltonen
Apr 22, 2017·The International Journal of Biological Markers·Francesca De IuliisSusanna Scarpa
Mar 18, 2020·Acta Biochimica Et Biophysica Sinica·Xiaodong LiJianhua Lin
May 30, 2019·Oncotarget·Gero Brockhoff
Jun 18, 2020·Translational Psychiatry·Liang Shi, Clare M Bergson
Mar 29, 2020·Cellular Oncology (Dordrecht)·Vincent F M SegersGilles W De Keulenaer
Jun 3, 2017·Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association·Sumi YunHye Seung Lee
Jan 5, 2021·Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·Takashi Masuko
Dec 20, 2020·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Isabel de LaveraAna P Zaderenko

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer: Therapeutic Approaches

Several different therapeutic approaches are used to treat breast cancer. These include chemotherapy, hormonal therapy, targeted therapy, and Immunotherapy. Discover the latest research on breast cancer therapeutic approaches here.

Cell Migration in Cancer and Metastasis

Migration of cancer cells into surrounding tissue and the vasculature is an initial step in tumor metastasis. Discover the latest research on cell migration in cancer and metastasis here.

Cell Migration

Cell migration is involved in a variety of physiological and pathological processes such as embryonic development, cancer metastasis, blood vessel formation and remoulding, tissue regeneration, immune surveillance and inflammation. Here is the latest research.